Recent News

• 05.14.2025 - LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
• 05.14.2025 - LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
• 04.16.2025 - LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
• 04.16.2025 - LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
• 03.28.2025 - LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
• 03.28.2025 - LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
• 02.25.2025 - LAVA Announces Evaluation of Strategic Options
• 02.25.2025 - LAVA Announces Evaluation of Strategic Options

Recent Filings

• 04.28.2025 - DEF 14A Other definitive proxy statements
• 04.28.2025 - ARS Annual Report to Security Holders
• 04.15.2025 - PRE 14A Other preliminary proxy statements
• 04.08.2025 - 3 Initial statement of beneficial ownership of securities
• 03.28.2025 - EX-99.1 EX-99.1
• 03.28.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.28.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.28.2025 - 8-K Current report
• 03.03.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.28.2025 - 8-K Current report